Genetic Cancer Risk: Testing Gaps Found
- A recent study reveals that a significant number of womb cancer patients are not receiving tests for Lynch syndrome, a genetic condition elevating their risk of developing further...
- Lynch syndrome, affecting approximately one in 300 individuals, frequently enough goes undiagnosed.
- The National Institute for Health and Care Excellence (NICE) advises that all womb and bowel cancer patients undergo tumor testing for markers of Lynch syndrome.
Many womb cancer patients are missing out on crucial Lynch syndrome testing, a key indicator of genetic cancer risk. A new study shows meaningful gaps exist in following NHS guidelines, leaving patients and families vulnerable. While tumor testing rates are high, the results aren’t always communicated effectively, hindering timely genetic counseling and blood tests. This failure to act on Lynch syndrome markers means many at-risk individuals aren’t getting the preventative care they need. Data from the UK and Ireland reveals that nearly half of eligible patients don’t receive the blood tests essential for diagnosis. These lapses in testing can lead to increased risks and missed opportunities. We at News Directory 3 find these outcomes alarming. What steps will be taken to close these testing gaps and protect more patients? Discover what’s next.
Significant Gaps in Lynch Syndrome Testing for Womb Cancer Patients
Updated June 9, 2025
A recent study reveals that a significant number of womb cancer patients are not receiving tests for Lynch syndrome, a genetic condition elevating their risk of developing further cancers.The research, published in BMJ Oncology, highlights critical gaps in adherence to NHS guidelines.
Lynch syndrome, affecting approximately one in 300 individuals, frequently enough goes undiagnosed. This inherited condition significantly increases susceptibility to womb and bowel cancer.Experts emphasize that diagnosing Lynch syndrome is vital for enabling proactive measures to reduce cancer risk, improve patient outcomes, and lower NHS costs.
The National Institute for Health and Care Excellence (NICE) advises that all womb and bowel cancer patients undergo tumor testing for markers of Lynch syndrome. Positive results should trigger referrals for genetic counseling and a blood test to confirm the diagnosis.
The University of Edinburgh-led study, encompassing over 2,500 womb cancer cases across the UK and Ireland from 2022 to 2023, found that while 91% of tumors were tested for Lynch syndrome markers, the results were not consistently communicated to clinical teams. Consequently, appropriate genetic counseling and blood tests were not arranged for many patients.
of those referred for genetic counseling, only two-thirds attended appointments.Long waiting lists contributed to high drop-out rates, with only 48% of eligible womb cancer patients ultimately receiving a blood test for Lynch syndrome. This genetic cancer risk assessment is crucial for early detection and preventative measures.
Thes lapses in bowel cancer and womb cancer testing leave many lynch syndrome patients undetected, increasing their risk of developing bowel cancer. Moreover, family members remain unaware of their potential risk.
Dr. Neil Ryan, the study lead and clinical lecturer at the University of Edinburgh, emphasized the importance of timely referrals for blood testing. “Despite clear guidance and excellent rates of tumor testing, too many women with Lynch syndrome are still being missed because they’re not referred for definitive blood testing in a timely way,” Ryan said. “This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected.”
Tumor testing is only cost-effective if it leads to diagnosis—we urgently need to make mainstream testing truly mainstream.
What’s next
The study underscores the urgent need for improved communication and streamlined referral processes to ensure that all eligible womb cancer patients receive appropriate testing and counseling for Lynch syndrome, reducing their risk of future cancers and protecting their families.